ReviewMediators of inflammation2014
Biological treatments in Behçet's disease: beyond anti-TNF therapy.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review.Rheumatology international · 2019Pooled it
- Behçet's Disease Presenting With Massive Haemoptysis Due to Pulmonary Artery Aneurysms: A Case Report.Cureus · 2026Article
- Comorbid Inflammatory Diseases in Behçet's Disease: A Multicenter Large Cohort Study.International journal of rheumatic diseases · 2026Observational
- Biosimilars in Adult and Pediatric Noninfectious Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Case Report: From idiopathic recurrent pericarditis to systemic Behçet's Disease: unmasking a unified IL-1-driven autoinflammatory phenotype.Frontiers in immunology · 2026Article
- Review
- Pemphigus Vulgaris Unmasked in a Patient With Behçet's Disease: A Complex Diagnostic Dilemma.Cureus · 2024Article
- Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.Frontiers in immunology · 2023Review
- Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.Frontiers in immunology · 2023Review
- New insights on multigenic autoinflammatory diseases.Therapeutic advances in musculoskeletal disease · 2022Review
- Clinical Manifestations and Management of Pediatric Behçet's Disease.Clinical reviews in allergy & immunology · 2021Review
- Use of non-TNF biologics for the treatment of neuro-Behçet's disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab.European journal of rheumatology · 2021Article
- Combined treatment of Taraxaci Herba and R7050 alleviates the symptoms of herpes simplex virus-induced Behçet's disease in rats.Integrative medicine research · 2021Article
- Behçet's disease presenting with massive hemoptysis related to bronchovascular fistula: A case report.Turk gogus kalp damar cerrahisi dergisi · 2021Article
- Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease.Frontiers in immunology · 2021Article
- Case Report: Repeated Low-Dose Rituximab Treatment Is Effective in Relapsing Neuro Behçet's Disease.Frontiers in neurology · 2021Article
- Pathogenesis of Non-Infectious Uveitis Elucidated by Recent Genetic Findings.Frontiers in immunology · 2021Review
- Superior vena caval obstruction: a rare presentation of Behcet's disease.BMJ case reports · 2020Article
- Behçet's Disease in Children: Diagnostic and Management Challenges.Therapeutics and clinical risk management · 2020Review
- Adalimumab in the treatment of pediatric Behçet's disease: case-based review.Rheumatology international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is universally recognized as a multisystemic inflammatory disease of unknown etiology with chronic course and unpredictable exacerbations: its clinical spectrum varies from pure vasculitic manifestations with thrombotic complications to protean inflammatory involvement of multiple organs and tissues. Treatment has been revolutionized by the progressed knowledge in the pathogenetic mechanisms of BD, involving dysfunction and oversecretion of multiple proinflammatory molecules, chiefly tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1β, and IL-6. However, although biological treatment with anti-TNF-α agents has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop off over time. Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. Different agents targeting various cytokines and their receptors or cell surface molecules have been studied: the IL-1 receptor has been targeted by anakinra, the IL-1 by canakinumab and gevokizumab, the IL-6 receptor by tocilizumab, the IL12/23 receptor by ustekinumab, and the B-lymphocyte antigen CD-20 by rituximab. The aim of this review is to summarize all current experiences and the most recent evidence regarding these novel approaches with biological drugs other than TNF-α blockers in BD, providing a valuable addition to the actually available therapeutic armamentarium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.